CRP influences endothelial activation and dysfunction by modifying endothelial vasoreactivity, primarily through a reduction in endothelial nitric oxide synthase (eNOS) activity, which may heighten the risk of atherothrombosis, hypertension, and CAD (37). This evidence concerns the gene NOS3 and hypertensive disorder.